An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapy An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly ...
A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed ca ...
Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunction of the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specify Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plas ...
Trade Name: DoxyHEXAL® tabs 100 mg Tabletten Product Name: DoxyHEXAL® tabs 100 mg Tabletten INN or Proposed INN: DOXYCYCLINE Trade Name: DoxyHEXAL® tabs 100 mg Tabletten Product Name: DoxyHEXAL® tabs 100 mg Tabletten INN or Pro ...
Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
120
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...